Shire to pay $56.5m to settle false claims violations
This article was originally published in Scrip
Executive Summary
Shire has agreed to pay $56.5m to settle civil allegations it violated the False Claims Act (FCA) as a result of its marketing and promotional practices involving its attention deficit/hyperactivity disorder (ADHD) medications Adderall XR (amphetamine/dextroamphetamine mixed salts), Vyvanse (lisdexamfetamine dimesylate) and Daytrana methylphenidate transdermal system) and its ulcerative colitis drugs Lialda (mesalamine) delayed-release tablets and Pentasa (mesalamine).
You may also be interested in...
Shire To Pay Record-Setting Device FCA Settlement
The $350m settlement resolves False Claims Act allegations Shire and its subsidiaries used tactics including lavish meals, free medical equipment, unearned speaker payments and cash to encourage doctors to prescribe the company’s Dermagraft human skin substitute.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.